Sei Investments Co. Purchases 66,746 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Sei Investments Co. lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 64.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,149 shares of the company’s stock after acquiring an additional 66,746 shares during the period. Sei Investments Co.’s holdings in Vaxcyte were worth $12,848,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its stake in shares of Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the last quarter. Fifth Third Bancorp purchased a new position in Vaxcyte in the 2nd quarter worth about $35,000. Fidelis Capital Partners LLC purchased a new position in Vaxcyte in the 1st quarter worth about $37,000. J.Safra Asset Management Corp lifted its stake in Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the period. Finally, Quest Partners LLC purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at about $70,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $84.26, for a total value of $1,263,900.00. Following the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at $40,351,102.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. The disclosure for this sale can be found here. Insiders sold a total of 78,283 shares of company stock worth $7,064,138 over the last three months. 3.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PCVX shares. Jefferies Financial Group boosted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Bank of America increased their price target on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th. Needham & Company LLC increased their target price on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $147.50.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $113.14 on Friday. The business’s fifty day moving average is $92.24 and its 200 day moving average is $77.80. The company has a market capitalization of $12.31 billion, a PE ratio of -26.43 and a beta of 0.97. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same period in the previous year, the firm earned ($0.70) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.